Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?The Motley Fool • 04/03/23
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People OfficerGlobeNewsWire • 03/08/23
Editas: The Potential Of Gene Editing Technology And The Risks Of A Lackluster PipelineSeeking Alpha • 02/24/23
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business UpdatesGlobeNewsWire • 02/22/23
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?The Motley Fool • 02/16/23
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate UpdateGlobeNewsWire • 02/15/23
Does Editas (EDIT) Have the Potential to Rally 51.55% as Wall Street Analysts Expect?Zacks Investment Research • 02/10/23
Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 01/30/23
Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 01/25/23